News Search Results
Jan 05, 2026, 11:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's
More news about: GenEditBio Limited
Jan 05, 2026, 10:30 ET Cell Culture Vessels Market worth $8.03 billion by 2030 | MarketsandMarkets™
https://www.marketsandmarkets.com/requestsampleNew.asp?id=75000041By end user, the pharmaceutical & biotechnology companies segment is expected to be the largest segment in the cell culture vessels market.the market for cell culture vessels has been segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories,
More news about: MarketsandMarkets
Jan 05, 2026, 10:05 ET North Carolina Named No. 1 in Site Selection Magazine's Annual Workforce Development Rankings
state's workforce ecosystem by delivering specialized training, biomanufacturing support and applied research services that enable life sciences and biotechnology companies to innovate and scale.Together, these programs deliver employer-driven workforce solutions across North Carolina, supporting
More news about: North Carolina Community College System
Jan 05, 2026, 10:00 ET Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain
placebo.About Nanjing Delova Biotech Co., Ltd.Nanjing Delova Biotech Co., Ltd., headquartered in Nanjing, China, is a commercial-stage biotechnology company focused on the development of novel non-opioid analgesics to address unmet medical needs globally. The company is advancing a series of
More news about: Nanjing Delova Biotech Co., Ltd.
Jan 05, 2026, 09:00 ET Morrison Foerster Elects 17 Partners
in the Litigation Department, based in Palo Alto. Her practice focuses on high-stakes patent and trade secret disputes in the life sciences and biotechnology sectors. She has significant experience representing leading innovators in matters involving biologics, antibody-drug conjugates, gene therapy,
More news about: Morrison Foerster
Jan 05, 2026, 08:34 ET BridGene Biosciences Appoints Nobel Laureate Bruce A. Beutler, M.D., to Scientific Advisory Board
other areas where innovative therapeutic approaches are urgently needed.About BridGene BiosciencesBridGene Biosciences is a biotechnology company focused on discovering and developing innovative small-molecule therapeutics for traditionally undruggable targets. Powered by its proprietary
More news about: BridGene Biosciences
Jan 05, 2026, 08:30 ET MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week (extended from
More news about: MetaVia Inc.
Jan 05, 2026, 08:05 ET SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson's disease
Jan. 5, 2026 /PRNewswire/ -- SynuSight Biotech ("SynuSight"), a biotechnology company dedicated to the development of diagnostic solutions for neurodegenerative diseases and ABLi Therapeutics ("ABLi"), a biotechnology company developing disease-modifying therapeutics in Parkinson's disease,
More news about: SynuSight Biotech
Jan 05, 2026, 08:00 ET Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson's Disease
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the California Institute for Regenerative Medicine
More news about: Kenai Therapeutics/BIOCOM
Jan 05, 2026, 07:00 ET NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of
More news about: NewcelX Ltd.
Jan 05, 2026, 07:00 ET Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Jan 05, 2026, 07:00 ET Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Jan 05, 2026, 06:00 ET IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. MorganA live audio webcast of the presentation and Q&A session will be available under the "Investors/Events"
More news about: IDEAYA Biosciences, Inc.
Jan 05, 2026, 03:15 ET GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's
More news about: GenEditBio Limited
Jan 04, 2026, 19:30 ET Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
to 200 molecules synthesized and tested in each program. About Insilico Medicine Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 04, 2026, 19:10 ET Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
development for the large diabetes treatment market."About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jan 02, 2026, 14:09 ET Hong Kong Tech Exhibits Immense Potential at CES 2026 with 61 Tech Companies Ready for Global Markets
and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland
More news about: Hong Kong Tech
Jan 02, 2026, 02:33 ET Last day of trading in shares with pre-emptive rights in connection with rights issue
company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created
More news about: Aquaporin A/S
Jan 02, 2026, 02:29 ET Last day of trading in shares with pre-emptive rights in connection with rights issue
company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created
More news about: Aquaporin A/S
Jan 01, 2026, 09:00 ET Immortal Dragons Comments on Longevity Regulation and Investment Trends Following FT Podcast Appearance
improving human healthspan. The fund currently supports more than 15 portfolio companies operating across diverse areas of longevity science and biotechnology. In addition to its investment activities, Immortal Dragons promotes longevity education and advocacy through book translation and publishing, translation
More news about: Immortal Dragons
Dec 30, 2025, 08:51 ET ROSM Selected to Lead Groundbreaking Clinical Trial for Osteoarthritis: $1M Grant Powers Search for Disease-Reversing Therapy
Collaboration with Global Potential This initiative is a testament to the power of Maryland's life sciences community. It brings together the biotechnology expertise of Britecyte, the clinical research capabilities of Amarex, and the patient-care excellence of ROSM. Together, these three organizations
More news about: Regenerative Orthopedics & Sports Medicine
Dec 30, 2025, 08:38 ET TOMO YUME Group Subsidiary SPARKLING SCIENCES Achieves Dual U.S. INCI Certifications, Accelerating Global Expansion of Advanced Exosome Ingredients
derived from Sparkling Sciences' advanced biotechnology, which integrates clinical-grade purification with freeze-drying processes:Human Hair Follicle Dermal Papilla Cell Exosomes (INCI ID: 40983)A premium biotechnology ingredient designed for advanced scalp
More news about: Sparkling Sciences
Dec 30, 2025, 07:00 ET Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical development, and business operations across the pharmaceutical, diagnostics, and agri-biotechnology sectors. Her prior
More news about: Evogene
Dec 30, 2025, 04:00 ET Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
productivity that improves human health."Global Capital Endorsement: AI‑driven Biotech Lands on HKEXAs a global pioneer AI‑driven biotechnology company, Insilico's Hong Kong listing, jointly sponsored by Morgan Stanley, CICC and GF Securities, attracted strong interest and active participation
More news about: Insilico Medicine
Dec 29, 2025, 10:01 ET Healthcare Cloud Computing Market to Reach $54.72 B by 2033 | CAGR 13% | According to DataM Intelligence Report
UserHospitals and health systemsAmbulatory care centersHealth insurance providersPharmaceutical and biotechnology companiesResearch institutions and digital health startupsRequest Customized Intelligence Aligned to Your Business Strategy:
More news about: DataM Intelligence 4 Market Research LLP